Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and CoXSWX:LLY +1.10%97 3-Year EPS without NRI Growth Rate is 45.00% as of Mar. 2026, which is 266% above its 10-year median of 12.30. GuruFocus rates XSWX:LLY with a GF Score™ of 97/100 and a GF Value™ of CHF1,123.95 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 789 Drug Manufacturers companies, Eli Lilly and Co ranks better than 86.44% on this metric.
During the past 12 months, Eli Lilly and Co's average EPS without NRI Growth Rate was 113.90% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 45.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 21.30% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 17.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Eli Lilly and Co was 49.00% per year. The lowest was -27.40% per year. And the median was 12.30% per year.
Eli Lilly and Co (XSWX:LLY) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Eli Lilly and Co 3-Year EPS without NRI Growth Rate Related Terms
XSWX:LLY vs JNJ, ABBV, MRK: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's 3-Year EPS without NRI Growth Rate falls into.
Eli Lilly and Co 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 45.00% mean?
Eli Lilly and Co (XSWX:LLY) has a 3-Year EPS without NRI Growth Rate of 45.00% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Eli Lilly and Co and its competitors. This is 266% above median its historical median of 12.30. According to the industry distribution chart, Eli Lilly and Co ranks #107 out of 789 companies in the Drug Manufacturers industry, placing it in the top 13.6%.
Is Eli Lilly and Co's 3-Year EPS without NRI Growth Rate too high?
Eli Lilly and Co's current 3-Year EPS without NRI Growth Rate of 45.00% is 266% above median its 10-year median of 12.30. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. Eli Lilly and Co's value of 45.00% is 368.8% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #107 out of 789 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's 3-Year EPS without NRI Growth Rate compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #107 out of 789 companies for 3-Year EPS without NRI Growth Rate. This places Eli Lilly and Co in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.60. Eli Lilly and Co's value of 45.00% is 368.8% above this benchmark. While the company's 10-year median is 12.30 vs. the industry median of 9.60, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 789 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current 3-Year EPS without NRI Growth Rate of 45.00% is 368.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current 3-Year EPS without NRI Growth Rate is 45.00%, which is 266% above median its own 10-year median of 12.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,123.95, compared to a current price of CHF920.00 — trading 18.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 45.00%, which is 266% above median its 10-year median of 12.30 and 368.8% above the Drug Manufacturers industry median of 9.60. Eli Lilly and Co's overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current 3-Year EPS without NRI Growth Rate is 45.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF920.00 is trading 18.1% below its estimated GF Value™ of CHF1,123.95.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
3-Year EPS without NRI Growth Rate: 45.00% (266% above median its 10-year median of 12.30)
GF Value™: CHF1,123.95 vs. price of CHF920.00 (18.1% below fair value)
Industry Position: 368.8% above the Drug Manufacturers median (#107 of 789)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
97GF Score
Get the complete analysis for XSWX:LLY
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
